SI1694318T1 - (S)-2-N-propilamino-5-hidroksitetralin kot terapevtsko sredstvo z agonističnim učinkom na D3 - Google Patents
(S)-2-N-propilamino-5-hidroksitetralin kot terapevtsko sredstvo z agonističnim učinkom na D3Info
- Publication number
- SI1694318T1 SI1694318T1 SI200430278T SI200430278T SI1694318T1 SI 1694318 T1 SI1694318 T1 SI 1694318T1 SI 200430278 T SI200430278 T SI 200430278T SI 200430278 T SI200430278 T SI 200430278T SI 1694318 T1 SI1694318 T1 SI 1694318T1
- Authority
- SI
- Slovenia
- Prior art keywords
- hydroxytetralin
- propylamino
- agonist
- dopa
- prodrugs
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- VCYPZWCFSAHTQT-NSHDSACASA-N (6s)-6-(propylamino)-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1=CC=C2C[C@@H](NCCC)CCC2=C1O VCYPZWCFSAHTQT-NSHDSACASA-N 0.000 title 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10359528A DE10359528A1 (de) | 2003-12-18 | 2003-12-18 | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
| PCT/EP2004/014143 WO2005058296A1 (de) | 2003-12-18 | 2004-12-13 | (s)-2-n-propylamino-5-hydroxytetralin als d3-agonistisches therapeutikum |
| EP04803781A EP1694318B1 (de) | 2003-12-18 | 2004-12-13 | (s)-2-n-propylamino-5-hydroxytetralin als d3-agonistisches therapeutikum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1694318T1 true SI1694318T1 (sl) | 2007-08-31 |
Family
ID=34683532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200430278T SI1694318T1 (sl) | 2003-12-18 | 2004-12-13 | (S)-2-N-propilamino-5-hidroksitetralin kot terapevtsko sredstvo z agonističnim učinkom na D3 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8609641B2 (sl) |
| EP (1) | EP1694318B1 (sl) |
| JP (1) | JP5253737B2 (sl) |
| KR (1) | KR101083568B1 (sl) |
| CN (1) | CN1929829B (sl) |
| AT (1) | ATE356621T1 (sl) |
| AU (1) | AU2004298341B2 (sl) |
| BR (1) | BRPI0417739A (sl) |
| CA (1) | CA2547820C (sl) |
| CY (1) | CY1106589T1 (sl) |
| DE (2) | DE10359528A1 (sl) |
| DK (1) | DK1694318T3 (sl) |
| ES (1) | ES2282923T3 (sl) |
| HR (1) | HRP20070175T3 (sl) |
| IS (1) | IS2533B (sl) |
| MX (1) | MXPA06006696A (sl) |
| PL (1) | PL1694318T3 (sl) |
| PT (1) | PT1694318E (sl) |
| RS (1) | RS50536B (sl) |
| SI (1) | SI1694318T1 (sl) |
| WO (1) | WO2005058296A1 (sl) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| DE10041479A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
| US8211462B2 (en) | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
| US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
| US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
| DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
| PT1426049E (pt) | 2002-12-02 | 2005-09-30 | Sanol Arznei Schwarz Gmbh | Administracao iontoforetica de rotigotina para o tratamento da doenca de parkinson |
| DE10261696A1 (de) * | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
| DE10334188B4 (de) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
| EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
| DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
| DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途 |
| EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
| EP2215072B1 (en) * | 2007-11-28 | 2015-09-02 | UCB Pharma GmbH | Polymorphic form of rotigotine |
| BRPI0920645A2 (pt) * | 2008-10-13 | 2016-01-12 | Interquim Sa | processo para a preparação de compostos de (s)-(-)-2-(n-propilamino_-5- metoxitetralma e (s)-(-)-2-(n-propilamino)-5-hidroxitetralina opticamente ativos |
| EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
| KR20120107075A (ko) * | 2009-10-16 | 2012-09-28 | 에파이오메드 테라퓨틱스, 아이엔씨. | 구토 치료 |
| JP5815556B2 (ja) | 2009-12-22 | 2015-11-17 | ウーツェーベー ファルマ ゲーエムベーハーＵｃｂ Ｐｈａｒｍａ Ｇｍｂｈ | 非結晶形態のロチゴチンの固体分散体を安定化するためのポリビニルピロリドン |
| ES2729824T3 (es) * | 2011-04-08 | 2019-11-06 | Laurus Labs Ltd | Formas sólidas de compuestos antirretrovirales, procedimiento para la preparación y composición farmacéutica de los mismos |
| EP2559435A1 (en) | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
| CN102634064B (zh) * | 2012-04-10 | 2013-09-11 | 宁波长阳科技有限公司 | 一种含磷阻燃剂、阻燃聚酯薄膜及其制备方法 |
| US9956201B2 (en) | 2014-07-21 | 2018-05-01 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms |
| WO2021206741A1 (en) * | 2020-04-09 | 2021-10-14 | Delahoussaye Kevin | Modulating neurotransmitter concentration |
| DE102021213721A1 (de) * | 2021-12-02 | 2023-06-07 | Continental Reifen Deutschland Gmbh | Verbindung, Kautschukmischung enthaltend die Verbindung, Fahrzeugreifen, der die Kautschukmischung in wenigstens einem Bauteil aufweist, Verfahren zur Herstellung der Verbindung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Antioxidationsmittel und/oder Farbstoff |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1017359A (en) * | 1972-07-03 | 1977-09-13 | Frederic P. Hauck | Substituted cyclic polymethylene phenols |
| EP0026848B1 (de) | 1979-09-14 | 1983-05-04 | Sandoz Ag | Tetralinderivate, ihre Herstellung und Heilmittel, welche diese Verbindungen enthalten |
| US4465692A (en) * | 1982-01-03 | 1984-08-14 | Nelson Research & Development Company | Selective D-2 dopamine receptor agonist |
| US5177112A (en) | 1983-01-03 | 1993-01-05 | Whitby Research, Inc. | Substituted 2-aminotetralins |
| FR2563731B1 (fr) * | 1984-05-07 | 1989-03-24 | Nelson Res & Dev | Composition therapeutique contenant de la 2-(n-phenylethyl-n-propylamino)-5-hydroxytetraline pour traiter la maladie de parkinson, pour stimuler selectivement les recepteurs de dopamine d-2 et procede de production d'une composition pharmaceutique utile au traitement de la maladie de parkinson |
| US5464632C1 (en) | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
| FR2679451B1 (fr) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
| WO1993023035A2 (en) | 1992-05-18 | 1993-11-25 | Smithkline Beecham Plc | Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease |
| SE9301732D0 (sv) | 1993-05-18 | 1993-05-18 | Haakan Wilhelm Wikstroem | New centrally acting 5-,6-,7-, and 8-substituted sulphone esters of n-monosubstituted 2-aminotetralins |
| US5382596A (en) * | 1993-08-05 | 1995-01-17 | Whitby Research, Inc. | Substituted 2-aminotetralins |
| US5442117A (en) | 1993-12-13 | 1995-08-15 | Albemarle Corporation | Enantiomeric resolution |
| IT1292155B1 (it) | 1997-06-13 | 1999-01-25 | Zambon Spa | Derivati naftotiazolonici attivi sul recettore dopaminergico d 3 |
| DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| FR2785538B1 (fr) | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | Comprime a delitement rapide perfectionne |
| DK1232152T3 (da) | 1999-11-23 | 2004-04-05 | Aderis Pharmaceuticals Inc | Forbedret fremgangsmåde til fremstilling af nitrogensubstituerede aminotetraliner |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| DE10041479A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| EP1256340B1 (en) | 2001-05-08 | 2003-08-13 | Schwarz Pharma Ag | Improved transdermal therapeutic system for the treatment of Parkinson's disease |
| US20030026830A1 (en) | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
| US20030027793A1 (en) | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
| DK1256339T3 (da) | 2001-05-08 | 2004-02-09 | Sanol Arznei Schwarz Gmbh | Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom |
| FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
| HUP0103986A2 (hu) * | 2001-09-28 | 2003-06-28 | Richter Gedeon Vegyészeti Gyár Rt. | Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| HU227543B1 (en) | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
| US20060263419A1 (en) | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
| CA2481934A1 (en) | 2002-04-18 | 2003-10-30 | Pharmacia Corporation | Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease |
| DE10220230A1 (de) | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
| US20040048779A1 (en) | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
| US20060216336A1 (en) | 2002-05-07 | 2006-09-28 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
| DE10234673B4 (de) | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
| US8246980B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
| US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
| US8211462B2 (en) | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
| PT1426049E (pt) | 2002-12-02 | 2005-09-30 | Sanol Arznei Schwarz Gmbh | Administracao iontoforetica de rotigotina para o tratamento da doenca de parkinson |
| DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
| DE10334188B4 (de) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| DE10334187A1 (de) | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
| DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
| EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
| DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| US20050197385A1 (en) | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
| DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| US20060024362A1 (en) | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
| TWI392670B (zh) | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途 |
| EP1987815A1 (en) | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
| EP2215072B1 (en) | 2007-11-28 | 2015-09-02 | UCB Pharma GmbH | Polymorphic form of rotigotine |
| EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
| JP5815556B2 (ja) | 2009-12-22 | 2015-11-17 | ウーツェーベー ファルマ ゲーエムベーハーＵｃｂ Ｐｈａｒｍａ Ｇｍｂｈ | 非結晶形態のロチゴチンの固体分散体を安定化するためのポリビニルピロリドン |
-
2003
- 2003-12-18 DE DE10359528A patent/DE10359528A1/de not_active Ceased
-
2004
- 2004-12-13 CN CN2004800373891A patent/CN1929829B/zh not_active Expired - Fee Related
- 2004-12-13 AT AT04803781T patent/ATE356621T1/de active
- 2004-12-13 SI SI200430278T patent/SI1694318T1/sl unknown
- 2004-12-13 RS RSP-2007/0117A patent/RS50536B/sr unknown
- 2004-12-13 ES ES04803781T patent/ES2282923T3/es not_active Expired - Lifetime
- 2004-12-13 AU AU2004298341A patent/AU2004298341B2/en not_active Ceased
- 2004-12-13 PT PT04803781T patent/PT1694318E/pt unknown
- 2004-12-13 WO PCT/EP2004/014143 patent/WO2005058296A1/de not_active Ceased
- 2004-12-13 US US10/587,637 patent/US8609641B2/en not_active Expired - Fee Related
- 2004-12-13 EP EP04803781A patent/EP1694318B1/de not_active Expired - Lifetime
- 2004-12-13 CA CA2547820A patent/CA2547820C/en not_active Expired - Fee Related
- 2004-12-13 HR HR20070175T patent/HRP20070175T3/xx unknown
- 2004-12-13 DK DK04803781T patent/DK1694318T3/da active
- 2004-12-13 JP JP2006544295A patent/JP5253737B2/ja not_active Expired - Fee Related
- 2004-12-13 DE DE502004003249T patent/DE502004003249D1/de not_active Expired - Lifetime
- 2004-12-13 BR BRPI0417739-8A patent/BRPI0417739A/pt not_active Application Discontinuation
- 2004-12-13 PL PL04803781T patent/PL1694318T3/pl unknown
- 2004-12-13 MX MXPA06006696A patent/MXPA06006696A/es active IP Right Grant
-
2006
- 2006-06-12 KR KR1020067011512A patent/KR101083568B1/ko not_active Expired - Fee Related
- 2006-06-12 IS IS8505A patent/IS2533B/is unknown
-
2007
- 2007-05-14 CY CY20071100652T patent/CY1106589T1/el unknown
-
2013
- 2013-10-25 US US14/063,821 patent/US9108900B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004298341B2 (en) | 2011-03-10 |
| CA2547820A1 (en) | 2005-06-30 |
| JP5253737B2 (ja) | 2013-07-31 |
| US20070197480A1 (en) | 2007-08-23 |
| ATE356621T1 (de) | 2007-04-15 |
| US9108900B2 (en) | 2015-08-18 |
| CY1106589T1 (el) | 2012-01-25 |
| BRPI0417739A (pt) | 2007-04-03 |
| AU2004298341A1 (en) | 2005-06-30 |
| EP1694318B1 (de) | 2007-03-14 |
| CN1929829A (zh) | 2007-03-14 |
| IS8505A (is) | 2006-06-12 |
| HRP20070175T3 (hr) | 2007-06-30 |
| RS50536B (sr) | 2010-05-07 |
| CA2547820C (en) | 2013-02-19 |
| US20140051768A1 (en) | 2014-02-20 |
| EP1694318A1 (de) | 2006-08-30 |
| KR101083568B1 (ko) | 2011-11-14 |
| JP2007514674A (ja) | 2007-06-07 |
| DE502004003249D1 (en) | 2007-04-26 |
| PT1694318E (pt) | 2007-05-31 |
| ES2282923T3 (es) | 2007-10-16 |
| CN1929829B (zh) | 2010-12-15 |
| KR20060126500A (ko) | 2006-12-07 |
| US8609641B2 (en) | 2013-12-17 |
| MXPA06006696A (es) | 2006-08-31 |
| WO2005058296A1 (de) | 2005-06-30 |
| HK1094421A1 (en) | 2007-03-30 |
| DK1694318T3 (da) | 2007-06-25 |
| PL1694318T3 (pl) | 2007-07-31 |
| DE10359528A1 (de) | 2005-07-28 |
| IS2533B (is) | 2009-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1694318T3 (pl) | (S)-2-N-propyloamino-5-hydroksytetrahydronaftalen jako D3-agonistyczny środek terapeutyczny | |
| SI1696905T1 (sl) | Substituirani 2-aminotetralini za preventivno zdravljenje Parkinsonove bolezni | |
| UY28473A1 (es) | Nuevos compuestos | |
| BR0311494A (pt) | Novos indóis substituìdos | |
| TW200510301A (en) | Novel compounds | |
| TW200728307A (en) | Novel spirochromanone derivatives | |
| MY162157A (en) | Substituted indole mcl-1 inhibitors | |
| TW200626068A (en) | Active compounds for seed treatment | |
| SG166820A1 (en) | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders | |
| SI2150530T1 (sl) | Substituirani sulfonamidni derivati | |
| IL173062A0 (en) | Substituted 2-aminotetralin for the treatment of depression | |
| MXPA04006031A (es) | Compuestos para el tratamiento de trastornos inflamatorios. | |
| MY158069A (en) | Tricyclic compound and pharmaceutical use thereof | |
| IL185410A0 (en) | Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease | |
| IL172290A0 (en) | Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain | |
| MX2010001304A (es) | Compuestos terapeuticos. | |
| WO2007104933A8 (en) | Chemical compounds | |
| UA89397C2 (ru) | Средство для профилактики или лечения депрессивных или тревожных расстройств | |
| TW200740766A (en) | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands | |
| ZA200800999B (en) | Use of N-dibenz (b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy | |
| MY141048A (en) | Morpholine derivatives as norepinephrine reuptake inhibitors | |
| DE602007008947D1 (en) | 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3-modulatoren | |
| MX2007012219A (es) | Medida de prevencion o remedio para neurosis paro depresion o ansiedad. |